Humanitarian Use Device (HUD): how it works and where it is recognized
A cross-border regulatory framework for supplying an unregistered or off-label medicine to a specific patient, on the order of a treating physician, under a defined permit issued by the destination-country medicines regulator.
Last reviewed 2026-05-16 by Reserve Meds clinical and regulatory team.
What HUD is
Origin and authorising body. United States Food and Drug Administration, Humanitarian Use Device designation under Section 520(m) of the Federal Food, Drug, and Cosmetic Act and 21 CFR 814 Subpart H. The authorising body for each individual case is the United States Food and Drug Administration (FDA), Center for Devices and Radiological Health (CDRH), acting under that jurisdiction's pharmacy or medicines legislation.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
Legal basis. Section 520(m) of the Federal Food, Drug, and Cosmetic Act authorises the FDA to grant Humanitarian Use Device (HUD) designation to a device intended to benefit patients by treating or diagnosing a disease or condition that affects or is manifested in not more than 8,000 individuals in the US per year. A device with HUD designation may then obtain Humanitarian Device Exemption (HDE) marketing authorisation under 21 CFR 814 Subpart H.
Humanitarian Use Device is a device-side parallel to orphan drug designation. The framework permits FDA market authorisation of devices for rare populations with a reduced effectiveness evidence requirement (devices must demonstrate probable benefit and safety, rather than the reasonable assurance of safety and effectiveness required for standard PMA approval). HUD and HDE devices have IRB-overseen use restrictions and limits on commercial profit margin until the population threshold is exceeded.
HUD and HDE is a device-specific framework and does not apply to medicines. The framework intersects with cross-border patient access when patients seek US-approved HUD or HDE devices that are not approved in their home country. The destination-country medical-device regulator (rather than the pharmacy regulator) handles import authorisation. This page is included in our pathway catalogue for completeness; for medicine access, see the named-patient and compassionate-use pages.
This page consolidates Reserve Meds's operational view of the Humanitarian Use Device (HUD) framework across the ten destination countries where we currently coordinate cross-border supply. Earlier in our content build we maintained separate per-country sub-pages for each Humanitarian Use Device (HUD)-in-country combination; those sub-pages remain available for archival reference but are no longer separately indexed, and the operational intelligence they carried has been folded into the country-compatibility table below.
Reserved for you.
Who can use HUD
HUD and HDE devices are used by US clinicians at IRB-approved sites for US patients meeting the device's indication. Cross-border patients seeking HUD or HDE devices use the destination-country medical-device import framework.
In practical terms, a Reserve Meds case opens when the treating physician has identified the clinical need, has reached a decision to prescribe a specific medicine, and has determined that the locally available route is unsuitable or unavailable. We then layer the regulatory and supply-chain coordination on top of that clinical decision; we do not originate the prescribing question and we do not advise on the clinical choice. The decision sits with the physician throughout.
Drug categories typically covered under HUD
This pathway is device-side, not drug-side. Categories include surgical implants for rare conditions, diagnostic devices for rare diseases, and therapeutic devices for paediatric subspecialty use.
The medicine itself must be source-country approved or in active regulatory development under a recognised reference authority (typically the US FDA, the European Medicines Agency, the UK MHRA, the Japan PMDA, or Health Canada). Most destination regulators will not authorise a Humanitarian Use Device (HUD) import for a medicine that lacks a recognised reference authorisation anywhere in the world, because the regulator's risk assessment leans on the source-country review as a substitute for its own.
Country compatibility
The table below summarises how the Humanitarian Use Device (HUD) framework is recognised across the ten destination countries where Reserve Meds currently coordinates cross-border supply. The "Accepts Humanitarian Use Device (HUD) dossiers" column reflects whether the destination regulator typically reviews and grants permits on the strength of a Humanitarian Use Device (HUD) clinical justification packet, or whether the patient must use a different parallel framework on the receiving side. Timelines reflect routine cases with a complete documentation set; first-import scenarios, paediatric weight-banded presentations, advanced therapy medicinal products, and large multi-cycle quantities can extend the regulator review by several weeks.
| Country | Local pathway equivalent | Accepts Humanitarian Use Device (HUD) dossiers? | Typical timeline | Local regulator |
|---|---|---|---|---|
| Bahrain | NHRA Compassionate / Special Import Permit | Not applicable (not a patient-access pathway) | 5 to 15 business days | NHRA |
| Egypt | EDA Single-Patient Import (Decree 425) | Not applicable (not a patient-access pathway) | 10 to 25 business days | EDA |
| India | Rule 36 personal-use import (D&C Rules 1945) | Not applicable (not a patient-access pathway) | 7 to 21 business days | CDSCO |
| Jordan | JFDA Compassionate / Special Use Import | Not applicable (not a patient-access pathway) | 10 to 20 business days | JFDA |
| Kuwait | MoH Unregistered Medicine Import Permit | Not applicable (not a patient-access pathway) | 10 to 20 business days | KDFC (MoH) |
| Lebanon | MoPH Special Import for Named Patient | Not applicable (not a patient-access pathway) | 10 to 25 business days | MoPH |
| Oman | MoH Compassionate / Named-Patient Import | Not applicable (not a patient-access pathway) | 10 to 20 business days | MoH-DGPADC |
| Qatar | MoPH Single-Patient Unregistered Drug Import | Not applicable (not a patient-access pathway) | 10 to 20 business days | MoPH-DPA |
| Saudi Arabia | SFDA Personal Importation Permit | Not applicable (not a patient-access pathway) | 10 to 25 business days | SFDA |
| United Arab Emirates | EDE Unregistered Medicine Import Permit | Not applicable (not a patient-access pathway) | 5 to 15 business days | EDE |
Notes. "Indirect" means the destination regulator does not directly accept Humanitarian Use Device (HUD) authorisation as the legal basis for import but does recognise a Humanitarian Use Device (HUD) authorisation as supporting precedent within its own named-patient or compassionate-use review. "Not applicable" means the framework is not a patient-access pathway in the cross-border sense and is shown here for completeness. Regulator names: NHRA (Bahrain), EDA (Egypt), CDSCO (India), JFDA (Jordan), KDFC (Kuwait), MoPH (Lebanon), MoH-DGPADC (Oman), MoPH-DPA (Qatar), SFDA (Saudi Arabia), and EDE (United Arab Emirates, federal from 29 December 2025).
Documentation required
A HUD application is typically assembled in coordination with the treating physician, the dispensing facility, and the cross-border supply partner. The documentation set below covers the routine case; specific destination countries may require additional items (most frequently a hospital ethics committee notification for paediatric or complex cases, and an insurer pre-authorisation letter where the patient intends to seek reimbursement).
- HUD designation request to the FDA (sponsor-led).
- HDE marketing application (sponsor-led).
- IRB approval at each using site.
- Patient informed consent specific to HUD or HDE use.
- Periodic safety reporting per HDE requirements.
Typical timeline
HUD designation: 45 days for FDA review of a complete request. HDE marketing application: 75 days for FDA review. Per-patient use at an IRB-approved site: rapid once the site has the IRB approval. Cross-border use: subject to destination-country medical-device regulator authorisation.
Costs and reimbursement
HDE devices may not be sold at a profit until the relevant population threshold is exceeded. Patient pricing varies by device.
Where Reserve Meds fits in
Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine access. For Humanitarian Use Device (HUD) cases, we coordinate the US-side sourcing through a DSCSA-compliant specialty channel, prepare the documentation packet your physician submits, coordinate validated cold-chain logistics with continuous temperature logging into the destination country, and assign a single named coordinator through the case. We do not replace your treating physician, we do not replace the destination-country regulator, and we do not replace your dispensing pharmacy. We coordinate the supply side so the physician can focus on patient care.
For each of the ten destination countries above, we publish a country-specific page documenting the operational realities (which dispensing facilities handle named-patient cases, how the cold chain is verified at the local airport, how the dispensing pharmacy releases the medicine, and what the typical insurer interaction looks like). Those country pages, combined with this pathway page and the specific drug pages, give the prescribing physician and the patient a coherent picture of what to expect before any commitment is made.
Our concierge fee is itemised separately on every firm quote alongside the drug acquisition cost, international logistics, customs, and dispensing pharmacy handling. The patient sees the full breakdown before deciding to proceed; we do not bundle costs and we do not charge an intake deposit. If the case cannot proceed for regulatory or supply reasons, we say so before any payment is taken.
Next step
If your treating physician has identified a clinical need that fits the Humanitarian Use Device (HUD) framework and you are weighing the cross-border route, the next step is a short intake. We confirm eligibility within 24 to 48 hours and send a documentation kit to your physician.
Reserved for you.